Table 1.

Antibodies used in this study

pAKT1, v-akt murine thymoma viral oncogene homolog 1, phosphorylated at Thr 308; EGFR, epithelial growth factor receptor; SHH, sonic hedgehog; SOS-1, Son of sevenless-1; TGF-β1, transforming growth factor-β1, eIF5A, eukaryotic translation initiation factor 5A; NFkB, nuclear factor kappa-light-chain-enhancer of activated B cells; PCNA, proliferating cell nuclear antigen; BCL-2, B-cell leukemia/lymphoma-2; FASL, FAS (CD95/Apo1) ligand; PARP, poly-ADP ribose polymerase; CEA, carcinoembryonic antigen; NF-1, neurofibromin-1; PIM1, pivotal integration site 1; PTCH1, patched homologue 1; STAT3, signal transducer and activator of transcription-3; α1-AT, α1-antitrypsin; TNFα, tumor nescrosis factor-α; CK, cytokeratin; EpCam, epithelial cell adhesion molecule, Ber-EP4; FAK, focal adhesion kinase; HSP-70, heat shock protein-70; KL1, pan cytokeratin 1, 2, 5, 6, 7, 8, 11, 14, 16, 17, 18; MMP, matrix metalloprotease; TGase, transglutaminase; HIF, hypoxia inducible factor; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.

^aSanta Cruz Biotechnology, Santa Cruz, CA, USA; ^bNeomarkers, Fremont, CA, USA; ^cDAKO, Glostrup, Denmark; ^dZymed, San Francisco, CA, USA.